$152.48+2.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $842M | $706.3M | +19.21% |
| Profit | $141.1M | $87.6M | +61.07% |
| Profit per share | $2.03 | $1.24 | +63.71% |
| Free Cash Flow | $66.4M | $100.1M | -33.67% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Insulet Corporation’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Insulet Corporation reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From Insulet Corporation's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$842M
+19% y/y
+5.0% q/q
Guided
—
No guide given
Actual
$2.03
+64% y/y
+48% q/q
Guided
—
No guide given
Actual
$189.8M
+61% y/y
+46% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.